Login to Your Account



Cellzome Lands Big GSK Deal: €475M for Inflammatory Diseases

By Nuala Moran


Wednesday, March 10, 2010

LONDON – Cellzome Ltd. signed its second big deal with GlaxoSmithKline plc, agreeing on a €475 million (US$644.3 million) collaboration to apply its epigenetics platform technology in the discovery of oral small-molecule drugs for treating immuno-inflammatory diseases. (BioWorld International)

 

BioWorld International Correspondent

 

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription